ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Unicycive Therapeutics, Inc. (UNCY) stock surged +0.38%, trading at $0.60 on NASDAQ, up from the previous close of $0.60. The stock opened at $0.60, fluctuating between $0.59 and $0.61 in the recent session.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Employees | 22 |
Beta | 2.15 |
Sales or Revenue | $675.00K |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep